Loading ETF research
Fetching the latest fund profile, holdings, and market data.
Fetching the latest fund profile, holdings, and market data.
Chicago Board Options Exchange · Sector Equity
$23.71
+$0.51 · +2.20%
· Aug 21, 3:59 PM ET
$23.71
Previous close+$0.51 · +2.20%
· Aug 21, 3:59 PM ET
$23.71
+$0.51 · +2.20%
Regular session · ET · Market data may be delayed.
This fund primarily aims to meet its investment goals by employing a representative sampling method. This means it selects a portion of the securities from its benchmark index, ensuring that this smaller selection closely reflects the broader index's risk profile, expected returns, and other key characteristics. The benchmark index itself is crafted to invest in global, exchange-listed companies that are poised for significant transformation through breakthroughs in genetic research and biotechnology. It's important to note that this fund is categorized as non-diversified.
Fund assets
2.59M USD
Expense ratio
0.45%
NAV
$21.32
Average volume
1.39K
Volume
10.26K
Day range
$23.22 – $23.76
52-week range
$14.14 – $24.09
Previous close
$23.20
Price change
1 day
+2.20%
1 month
+18.49%
3 months
+35.02%
Year to date
+40.46%
1 year
+65.57%
3 years
+44.13%
5 years
-11.17%
Price changes exclude distributions, fees, taxes, and investor-specific cash flows.
Portfolio
Holdings data updated May 15, 2026.
Portfolio composition
Fund income
Dec 26, 2025
Annual
Dec 26, 2025
Dec 30, 2025
$0.7705
Dec 26, 2024
Annual
Dec 26, 2024
Dec 30, 2024
$0.1071
Dec 22, 2023
Annual
Dec 26, 2023
Dec 28, 2023
$0.135
Dec 23, 2022
Annual
Dec 27, 2022
Dec 29, 2022
$0.0653
Dec 27, 2021
Annual
Dec 28, 2021
Dec 30, 2021
$0.0246
Latest coverage
No ETF news is currently available.
More funds
Continue in GoAI
Connect this ETF with broader market context and continue your research in GoAI.
ETF data may be delayed, incomplete, or revised. Holdings and exposures change over time. Historical performance does not guarantee future results. This page is for informational and educational purposes only and does not constitute investment advice or a recommendation.
